Compare SLND & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SLND | PLX |
|---|---|---|
| Founded | 1900 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 178.6M | 204.9M |
| IPO Year | N/A | 1998 |
| Metric | SLND | PLX |
|---|---|---|
| Price | $3.50 | $1.75 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $4.00 | ★ $12.00 |
| AVG Volume (30 Days) | 50.6K | ★ 522.3K |
| Earning Date | 11-12-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.07 |
| Revenue | ★ $935,461,000.00 | $61,840,000.00 |
| Revenue This Year | N/A | $14.29 |
| Revenue Next Year | $0.96 | $16.65 |
| P/E Ratio | ★ N/A | $25.92 |
| Revenue Growth | N/A | ★ 35.41 |
| 52 Week Low | $2.68 | $1.32 |
| 52 Week High | $5.34 | $3.10 |
| Indicator | SLND | PLX |
|---|---|---|
| Relative Strength Index (RSI) | 46.27 | 44.67 |
| Support Level | $3.48 | $1.74 |
| Resistance Level | $3.92 | $1.85 |
| Average True Range (ATR) | 0.25 | 0.09 |
| MACD | 0.04 | 0.02 |
| Stochastic Oscillator | 35.52 | 51.35 |
Southland Holdings Inc is an infrastructure construction company in North America. The company's infrastructure projects range from water conveyance systems and tunnels to long-span bridges and vertical structures. The company operates in two distinct segments: Civil and Transportation. The civil segment operates throughout North America and specializes in services that include the design and construction of water pipelines, pump stations, lift stations, water and wastewater treatment plants, concrete and structural steel, outfall, and tunneling. The transportation segment operates throughout North America and specializes in services that include the design and construction of bridges, roadways, marine, dredging, ship terminals and piers, and specialty structures and facilities.
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.